Why pemphigus vulgaris starts in the mouth — and pemphigus foliaceus never touches it
Two diseases in the same family, driven by antibodies against two closely related proteins, and they do almost opposite things. Pemphigus vulgaris frequently begins with erosions in the mouth and may not touch the skin for months. Pemphigus foliaceus produces crusted, flaking lesions on the scalp, face and trunk and spares the mucosa entirely.
That is not a quirk. It is the most elegant piece of reasoning in this whole field, and once you understand it, your own antibody report stops being a set of numbers and becomes a map of where your disease is going.
It is called the desmoglein compensation theory.
The rivets, and where they are
Keratinocytes are held to each other by desmosomes. Desmogleins are the proteins that reach across the gap between two cells and lock them together. Two of them matter here:
- Desmoglein 3 (Dsg3)
- Desmoglein 1 (Dsg1)
The critical fact is that they are not distributed evenly, and the distribution is different in skin than it is in mucosa.
In the skin: Dsg1 is present throughout the epidermis, and is most concentrated in the superficial layers. Dsg3 is concentrated in the deeper layers, near the base.
In mucosa — the lining of the mouth, throat, oesophagus — the arrangement flips. Dsg3 is strongly expressed throughout. Dsg1 is present only at low levels.
The rule
A desmosome can survive losing one desmoglein if the other one is present in that layer in sufficient quantity to hold the join. Blisters form only where the attacked desmoglein has no partner to compensate.
That single rule predicts everything.
Case one: antibodies against Dsg3 alone
This is classic, mucosa-dominant pemphigus vulgaris.
- In the mouth: Dsg3 is doing nearly all the work, and Dsg1 is too weakly expressed to take over. Knock out Dsg3 and the join fails. Erosions. The mouth goes first.
- In the skin: Dsg3 is attacked in the deeper layers — but Dsg1 is also present there, and it compensates. The skin holds. Little or no skin blistering.
This is why so many people with pemphigus vulgaris spend months being treated by dentists, ENT surgeons and general physicians for "recurrent ulcers", "aphthous ulcers", "thrush", "gingivitis" — with no skin sign at all to make anyone suspicious.
An adult with painful oral erosions that will not heal, and no other explanation, is pemphigus until a biopsy says otherwise. If that is you, ask for the biopsy now, not after the next course of antifungal.
Case two: antibodies against Dsg1 alone
This is pemphigus foliaceus.
- In the skin: in the superficial layers, Dsg1 is the dominant protein and Dsg3 is essentially absent. Nothing compensates. The join fails high in the epidermis, producing the shallow, scaly, crusted, flaking lesions of PF. Because the split is so superficial, the "blister" is often never seen intact — it is already a crust by the time you look at it.
- In the mouth: Dsg3 is everywhere and abundant. It compensates comfortably for the loss of Dsg1. The mucosa is spared.
Case three: antibodies against both
This is mucocutaneous pemphigus vulgaris. Nothing compensates anywhere. Mouth and skin. This is the more extensive form, and it is often how the disease evolves: someone who began with anti-Dsg3 and oral disease develops anti-Dsg1 and, with it, skin lesions.
That evolution has a name — epitope spreading — and it is the reason your ELISA is repeated rather than done once and filed.
What this means for your own report
Your anti-Dsg1 and anti-Dsg3 values are not trivia. They predict phenotype.
- Dsg3 positive, Dsg1 negative → expect mucosal disease. Watch the mouth, throat and oesophagus. Watch your weight.
- Dsg1 positive, Dsg3 negative → expect superficial skin disease; mucosa likely spared.
- Both positive → expect both.
- A new anti-Dsg1 appearing in someone who previously had anti-Dsg3 alone is a warning that the disease may be about to involve skin. That is a conversation to have with your dermatologist before it happens, not after.
The honest limits of the theory
This is a model, not a law, and we would rather you knew where it leaks.
- Not every anti-desmoglein antibody causes blisters. Pathogenicity depends heavily on which part of the molecule is bound; antibodies against the outer, amino-terminal regions are the damaging ones. Some people with detectable antibody have quiet disease.
- There are exceptions to the clinical pattern. Some patients with anti-Dsg3 alone do get skin lesions.
- Desmogleins are not the only targets. Antibodies against other desmosomal proteins, including desmocollins, exist and complicate the picture.
- The theory explains the pattern extremely well. It does not explain why your immune system started making the antibody in the first place. Nobody can tell you that with confidence — not your dermatologist, and not us.
Why this determines how you should be treated
If your disease is mucosa-dominant, three things follow.
First, "just the mouth" is not mild. Oral pemphigus vulgaris is the classic opening of the more serious form of the disease. Erosions in the mouth, throat and oesophagus stop people eating. Weight loss and malnutrition are disease features, not side issues. Pain on swallowing, hoarseness, or food sticking are things to report immediately.
Second, surface treatment cannot reach it. A topical is applied to a surface that is constantly washed, chewed and swallowed over. In a disease driven by circulating antibody produced by plasma cells in lymph nodes and bone marrow, treating the mouth from the mouth is treating the last link in a long chain.
Third, conventional treatment is decided on exactly this basis. Moderate-to-severe pemphigus vulgaris is treated systemically — current guidance places rituximab, alongside a steroid course, as first-line. Those decisions belong to your dermatologist. Not to us. You do not stop, taper or substitute any prescribed drug — steroid, rituximab, azathioprine, mycophenolate — because of anything you read here. Any change is made by the doctor who prescribed it.
Where EPOH fits, and why the topicals come fourth
EPOH is entirely formulation-based: oral compounds and topical preparations, couriered to you and taken at home. There is no procedure, no in-clinic therapy, and no clinic visit at any stage.
It runs in one order — LIFES — and the order is the medicine:
- Phase L — Lowering Inflammatory Load
- Phase I — Internal Healing & Gut Repair
- Phase F — Functional Detox & Immune Balancing
- Phase E — External Care & Local Reversal — the topical preparations you apply at home
- Phase S — Sustaining Remission
The desmoglein compensation theory is, in effect, the argument for that order. The disease is decided by an antibody made deep in the immune system and delivered by the bloodstream. The mouth is where it lands, not where it lives. Phase E is fourth because the surface is the last mile, not the first.
And there is a rule that matters more than any of this: Phase F, run before L and I are stable, mobilises internal load faster than the system can clear it — and the condition gets worse. People who started their Ayurvedic treatment with a "cleanse" or a "detox" and flared did not encounter a wrong approach. They encountered the wrong timing.
The timeline, without decoration
The first four to eight weeks are internal work. Visible change on the surface is not expected in that window. Between months two and four, the disease should begin to change — fewer new erosions, faster closure, less mucosal pain, a titre trend that is moving in the right direction. Stable remission is assessed from month eight onwards.
We do not promise a cure. We aim at sustained remission, alongside your dermatologist, never in place of them. And if your mouth is not letting you eat, that is not a case for patience — that is a case for your dermatologist, today.
